ARROWHEAD RESEARCH CORP | 3,882 Euro | -0,088 -2,22 % | |
| WKN: A1JPJ3 ISIN: US0427972098 Ticker-Symbol: HDP1 | Frankfurt | 13.02.12 | 08:20 Uhr |
Branche DienstleistungenAktienmarkt Sonstige |
|
| Zeit | Aktuelle Nachrichten | Leser | Medien | |
|---|---|---|---|---|
| 09.02. | Arrowhead Reports Fiscal 2012 First Quarter Financial Results | 27 | Business Wire | |
| Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine
company with development programs in oncology and obesity, today
announced financial results for its fiscal... Mehr lesen zu: Arrowhead Reports Fiscal 2012 First Quarter Financial Results | ||||
| 02.02. | Arrowhead to Report Fiscal 2012 First Quarter Financial Results | 27 | Business Wire | |
| Conference call Scheduled for Thursday, February 9, 2012
Arrowhead Research Corporation (NASDAQ:ARWR) today announced that it
will report its financial... Mehr lesen zu: Arrowhead to Report Fiscal 2012 First Quarter Financial Results | ||||
| 05.01. | Alnylam and Arrowhead Form Collaboration and Licensing Agreement | 52 | Business Wire | |
| – Arrowhead Receives License from Alnylam to Develop RNAi Therapeutic
Toward Hepatitis B Virus (HBV) –
– Alnylam Gains Access to Arrowhead's Dynamic Polyconjugate... Mehr lesen zu: Alnylam and Arrowhead Form Collaboration and Licensing Agreement | ||||
| 04.01. | Arrowhead Announces FDA Clearance to Initiate AdipotideTM Phase I Clinical Trial | 25 | Business Wire | |
| Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company
with development programs in oncology and obesity, today announced that
the Investigational New Drug... Mehr lesen zu: Arrowhead Announces FDA Clearance to Initiate AdipotideTM Phase I Clinical Trial | ||||
| 20.12. | Arrowhead Reports Fiscal 2011 Fourth Quarter and Year-End Financial Results | 18 | Business Wire | |
| Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company
with development programs in oncology and obesity, today announced
financial results for its fiscal... Mehr lesen zu: Arrowhead Reports Fiscal 2011 Fourth Quarter and Year-End Financial Results | ||||
| 19.12. | Arrowhead Appoints Michael S. Perry, DVM, Ph.D. to Board of Directors | 20 | Business Wire | |
| Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company
with development programs in oncology and obesity, announced today that
it has appointed Michael... Mehr lesen zu: Arrowhead Appoints Michael S. Perry, DVM, Ph.D. to Board of Directors | ||||
| 15.12. | Arrowhead to Report Fiscal 2011 Fourth Quarter and Year-End Financial Results | 26 | Business Wire | |
| Conference call Scheduled for Tuesday, December 20, 2011
Arrowhead Research Corporation (NASDAQ:ARWR) today announced that it
will report its financial... Mehr lesen zu: Arrowhead to Report Fiscal 2011 Fourth Quarter and Year-End Financial Results | ||||
| 23.11. | Arrowhead Research Appoints Drs. David Lewis and David Rozema to Lead Operations at Madison, WI Facility | 31 | Business Wire | |
| Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine
company with development programs in oncology, obesity, and regenerative
medicine, today announced that it... Mehr lesen zu: Arrowhead Research Appoints Drs. David Lewis and David Rozema to Lead Operations at Madison, WI Facility | ||||
| 17.11. | FRA: DELETION OF INSTRUMENTS FROM XETRA - 17.11.2011 | 87 | Xetra Newsboard | |
| The following instruments on XETRA do have their last trading day on 17.11.2011 Die folgenden Instrumente in XETRA haben ihren letzten Handelstag am 17.11.2011 ISIN Name BE0932179097 BELGACOM 06-11... Mehr lesen zu: FRA: DELETION OF INSTRUMENTS FROM XETRA - 17.11.2011 | ||||
| 17.11. | VCG, HDP, E6FN: AENDERUNG / CHANGE ISIN | 62 | Xetra Newsboard | |
| FUER FOLGENDE INSTRUMENTE WERDEN ISIN, WKN UND KUERZEL GEAENDERT. GUELTIG AB: 18.11.2011. FOR THE FOLLOWING INSTRUMENTS ISIN, WKN AND SHORT CODE WILL CHANGE. VALID FROM NOVEMBER 18, 2011. Einstellung... Mehr lesen zu: VCG, HDP, E6FN: AENDERUNG / CHANGE ISIN | ||||
| 17.11. | HDP: AUSSETZUNG/SUSPENSION | 51 | Xetra Newsboard | |
| DIE FOLGENDE AKTIE IST AB SOFORT AUSGESETZT: THE FOLLOWING SHARE IS SUSPENDED WITH IMMEDIATE EFFECT: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL ARROWHEAD RESEARCH CORP HDP US0427971009 BAW/UFN Mehr lesen zu: HDP: AUSSETZUNG/SUSPENSION | ||||
| 16.11. | Arrowhead Research Announces 1-for-10 Reverse Stock Split | 32 | Business Wire | |
| Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine
company with development programs in oncology, obesity, and regenerative
medicine, today announced the implementation... Mehr lesen zu: Arrowhead Research Announces 1-for-10 Reverse Stock Split | ||||
| 10.11. | Arrowhead Research Subsidiary Ablaris Therapeutics Data Published in Science Translational Medicine Demonstrates Weight Loss in Obese Monkeys | 77 | Business Wire | |
| Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine
company with development programs in oncology, obesity, and regenerative
medicine, today announced the publication... Mehr lesen zu: Arrowhead Research Subsidiary Ablaris Therapeutics Data Published in Science Translational Medicine Demonstrates Weight Loss in Obese Monkeys | ||||
| 07.11. | Arrowhead Research Publishes White Paper on RNAi Delivery Technology Acquired from Roche | 56 | Business Wire | |
| - A Well-Designed and Powerful Solution to the siRNA Delivery
Challenge -
Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine
company... Mehr lesen zu: Arrowhead Research Publishes White Paper on RNAi Delivery Technology Acquired from Roche | ||||
| 03.11. | Arrowhead Research Appoints Brendan P. Rae, Ph.D., J.D., Chief Business Officer | 31 | Business Wire | |
| Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine
company with development programs in oncology, obesity, and regenerative
medicine, today announced that it... Mehr lesen zu: Arrowhead Research Appoints Brendan P. Rae, Ph.D., J.D., Chief Business Officer | ||||
| 02.11. | Vascular Research Further Validates the Drug Development Programs of Arrowhead Research Subsidiary Ablaris Therapeutics and Alvos Therapeutics | 26 | Business Wire | |
| Arrowhead Research Corporation (NASDAQ: ARWR) today announced
that a paper further validating the drug development programs of Ablaris
Therapeutics, Inc., a subsidiary... Mehr lesen zu: Vascular Research Further Validates the Drug Development Programs of Arrowhead Research Subsidiary Ablaris Therapeutics and Alvos Therapeutics | ||||
| 27.10. | Arrowhead Research Appoints Bruce Given M.D. Chief Operating Officer | 25 | Business Wire | |
| Arrowhead Research Corporation (NASDAQ: ARWR) today announced
that it has appointed Bruce Given, M.D. to the position of Chief
Operating Officer of the Company effective... Mehr lesen zu: Arrowhead Research Appoints Bruce Given M.D. Chief Operating Officer | ||||
| 24.10. | Arrowhead Research Buys RNA Therapeutics Assets From Roche | 68 | AFX News | |
| WASHINGTON (dpa-AFX) - Arrowhead Research Corp. (ARWR) said it has acquired
RNA therapeutics assets from Roche (RHHBY.PK) including the research site in
Madison.The Roche assets and IP acquired... Mehr lesen zu: Arrowhead Research Buys RNA Therapeutics Assets From Roche | ||||
| 24.10. | Arrowhead Research Corporation Acquires Roche RNA Assets and Site | 54 | Business Wire | |
| Three New Delivery Technologies, Broad RNAi IP, and Advanced
Operations to Drive Clinical Development, Partnerships, and RevenueRoche
Takes Equity Stake in Arrowhead and... Mehr lesen zu: Arrowhead Research Corporation Acquires Roche RNA Assets and Site | ||||
| 04.10. | Arrowhead Research Corporation Completes $5.5 Million Private Placement | 47 | Business Wire | |
| At Market Offering Led by Noted Investor, Jim Mellon; Proceeds to
Fund Nanomedicine Programs
Arrowhead Research Corporation (NASDAQ: ARWR)... Mehr lesen zu: Arrowhead Research Corporation Completes $5.5 Million Private Placement | ||||
Startseite • Nachrichten • Aktienkurse • Xetra-Orderbuch • Watchlist
Ad hoc-Mitteilungen • Chartanalysen • Nachrichten Börsen • Aktien-Empfehlungen
Branchen • Medien • Nachrichten-Archiv
Impressum | AGB | Disclaimer • Presse • Mediadaten
RSS-News von FinanzNachrichten.de kostenlos für Ihren Browser und Ihre Homepage
